bioMerieux (OTCMKTS:BMXMF) Shares Gap Up – Still a Buy?

Shares of bioMerieux (OTCMKTS:BMXMF) gapped up before the market opened on Wednesday. The stock had previously closed at $83.27, but opened at $88.6650. bioMerieux shares last traded at $88.6650, with a volume of 51 shares traded.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BMXMF shares. Piper Sandler began coverage on shares of bioMerieux in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of bioMerieux in a report on Wednesday, June 17th. Zacks Research upgraded bioMerieux from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, Morgan Stanley reissued an “underweight” rating on shares of bioMerieux in a report on Friday, September 11th. Five research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, bioMerieux currently has a consensus rating of “Reduce”.

bioMerieux Price Performance

The company has a 50 day moving average price of $82.98 and a 200-day moving average price of $87.89. The company has a quick ratio of 1.48, a current ratio of 2.39 and a debt-to-equity ratio of 0.08.

bioMerieux Company Profile

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics.